 |
June 17, 2010
Arno Therapeutics Announces Dosing of First Patient in a Phase I/IIa Study of AR-42, a broad spectrum histone and non-histone deacetylation inhibitor (pan-DAC) more »
December 17, 2009
Arno Therapeutics Announces Enrollment of First Patient in Phase II Study of AR-67 in Patients with Glioblastoma Multiforme (GBM) more »
December 15, 2009
Arno Therapeutics Announces Poster Presentation at ASH Annual Meeting Demonstrating Anti-Leukemic Stem Cell Activity of AR-42 more »
|
 |
Ohio State University cancer researchers are recruiting patients to a phase I clinical trial for a new drug designed to inhibit the growth of solid tumors. The phase I clinical trial will assess the safety and early evidence of activity of AR-12 » Read
Arno’s AR-12 and AR-42 featured as examples of the Ohio State University’s translation scientific findings from the bench to the bedside » Read
|
|
